ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

ADCT ADC Therapeutics SA

4,72
-0,04 (-0,84%)
19 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
ADC Therapeutics SA ADCT NYSE Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
-0,04 -0,84% 4,72 22:00:04
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
4,76 4,60 4,92 4,72 4,76
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
04/4/202413:00GLOBEADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial..
03/4/202413:00GLOBEADC Therapeutics to Host a Virtual Research Investor Event..
01/4/202422:05GLOBEADC Therapeutics Makes Grants to New Employees Under..
13/3/202412:03IHMARKETNEWSMixed Futures Amidst Quiet Economic Schedule; Oil Prices..
13/3/202412:00GLOBEADC Therapeutics Reports Fourth Quarter and Full Year 2023..
06/3/202413:15GLOBEADC Therapeutics to Participate in the Guggenheim 5th Annual..
06/3/202413:00GLOBEADC Therapeutics to Host Fourth Quarter and Year-End 2023..
05/3/202423:45GLOBEADC Therapeutics Announces Abstracts Accepted for..
05/3/202415:15EDGAR2Form 8-K - Current report
29/2/202422:30EDGAR2Form 8-K - Current report
27/2/202413:00GLOBEADC Therapeutics to Participate in the TD Cowen 44th Annual..
24/1/202414:00EDGAR2Form 8-K - Current report
19/1/202422:30EDGAR2Form 8-K - Current report
04/1/202413:15EDGAR2Form 8-K - Current report
04/1/202413:15GLOBEADC Therapeutics Regains Compliance with NYSE Continued..
04/1/202413:00EDGAR2Form 8-K - Current report
04/1/202413:00GLOBEADC Therapeutics Provides Business Updates
03/1/202402:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
03/1/202402:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
03/1/202402:04EDGAR2Form 3 - Initial statement of beneficial ownership of..
03/1/202402:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
03/1/202401:59EDGAR2Form 3 - Initial statement of beneficial ownership of..
03/1/202401:58EDGAR2Form 3 - Initial statement of beneficial ownership of..
19/12/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/12/202322:25EDGAR2Form S-8 - Securities to be offered to employees in employee..
12/12/202311:15GLOBEADC Therapeutics Announces Initial Results from..
04/12/202322:57EDGAR2Form S-8 - Securities to be offered to employees in employee..
20/11/202308:40PRNUSSobi to present new data at ASH 2023 Annual Meeting
15/11/202309:00GLOBEMyricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur..
07/11/202313:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/11/202313:15GLOBEADC Therapeutics Receives NYSE Notice of Non-Compliance With..
07/11/202313:13EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/11/202313:00GLOBEADC Therapeutics Reports Third Quarter 2023 Financial..
06/11/202313:00GLOBEADC Therapeutics to Participate in the Jefferies London..
02/11/202315:10GLOBEADC Therapeutics Announces Abstracts Accepted for..
24/10/202313:00GLOBEADC Therapeutics to Host Third Quarter 2023 Financial..
04/10/202310:00GLOBEMyricx Expands its ADC Expertise with the Appointment of..
11/9/202313:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202313:00GLOBEADC Therapeutics to Participate in September Investor..
31/8/202301:32GLOBEADC Therapeutics Announces Updates on ZYNLONTA® LOTIS..
08/8/202313:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/8/202313:00GLOBEADC Therapeutics Reports Second Quarter 2023 Financial..
01/8/202313:00GLOBEADC Therapeutics to Host Second Quarter 2023 Financial..
24/7/202313:21GLOBEOverland ADCT BioPharma Announces NMPA Accepts Biologics..
20/7/202322:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/7/202322:05GLOBEADC Therapeutics Announces Plan to Discontinue the Phase 2..
11/7/202315:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/7/202313:00GLOBEADC Therapeutics Announces Voluntary Pause of Enrollment in..
15/6/202313:15GLOBEADC Therapeutics Announces Evolution of Board of Directors
09/6/202313:15GLOBEADC Therapeutics Announces Updated LOTIS-2 Results..

Dernières Valeurs Consultées

Delayed Upgrade Clock